Skip to Navigation Skip to Search Skip to Content
Search All Centers

A Look Ahead: Expert Perspective on CAR-T Cell Therapy vs. Transplants

Read Transcript

Published on September 12, 2018

What does the future hold for CAR-T cell therapy and the standard of care for multiple myeloma? Will CAR-T cell therapy replace transplants? Myeloma experts Dr. Amrita Krishnan, from City of Hope, and Dr. Joshua Richter, from Mount Sinai School of Medicine, discuss current clinical trial research and explain how this approach compares to other approved myeloma therapies. What is the patient response? How will CAR-T cell therapy fit in with the current treatment landscape? Watch now to find out more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc., Celgene Corporation, and Takeda Oncology for their support.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | A Look Ahead: Expert Perspective on CAR-T Cell Therapy vs. Transplant in Myeloma

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

What we are looking at is the trial that was going to open through the BMT CTN (Blood & Marrow Transplant Clinical Trials Network) is patients that have very, very high-risk myeloma doing CAR-T cells after an autologous transplant. So really in a way you're trying to get the best of both worlds.  

The only type of transplant that limits options for CAR-T is allogeneic stem cell transplant, makes you ineligible for many but not all of the CAR-T protocols.  But, again, the decision of which way to go now is going to change in the future and this is a conversation you should definitely have with your care team.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.